Skip to content

Telix Pharmaceuticals

US · TLX #2345 by market cap Listed 2024
8.37 -0.34 -3.90%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.53 In line with history 36th percentile
5-year average 9.37 · #439 of 514 in Biotechnology
P/E ratio 95.15 In line with history 40th percentile
5-year average 40.89 · forward 312.55 · #73 of 77 in Biotechnology
P/S ratio 3.51 Cheap vs history 23rd percentile
5-year average 5.89 · forward 3.09 · #93 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Telix Pharmaceuticals (TLX) 2.84B 86.29 6.83 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value11.60 Economic moatNone UncertaintyHigh

Trading 38.6% below Morningstar's fair value estimate.

Fair value

Telix Pharmaceuticals Ltd is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 20% discount to our quantitative fair value estimate of $11.60 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet bolsters our estimated valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of 1.6 falls in the bottom 20% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.7%, for example, falls in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Telix Pharmaceuticals discussion 0 comments

Add a comment